SESarah Jl Edwards

Sarah Jl Edwards

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Jl Edwards has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Guest editorial: Accommodating cultural differences in the International Conference of Harmonisation Good Clinical Practice guidelines

    by Rakhshi Memon, Bushra Ali Shah, Muqaddas Asif, Ozlem Eylem-Van Bergeijk, Dung Ezekiel Jidong, Tarela Juliet Ike, Ameer B Khoso, Tayyeba Kiran, Neha Omar, Farah Lunat, et al.

  • Open Access

    Effectiveness of YCMAP (youth culturally adapted manual assisted problem solving) intervention in adolescents after self-harm in Pakistan: multicentre, randomised controlled trial

    by Nusrat Husain, Sehrish Tofique, Tayyeba Kiran, Matthias Pierce, Imran B Chaudhry, M Omair Husain, Rakhshi Memon, Ahmed Waqas, Nadeem Gire, Sarah Edwards, et al.

    Objective To evaluate the clinical effectiveness of the YCMAP intervention (Youth Culturally Adapted Manual Assisted Problem Solving) for adolescents after self-harm in Pakistan. Design Multicentre, randomised controlled trial that compared YCMAP with enhanced treatment as usual. Settings General practices, emergency departments, medical wards of participating hospitals, and community centres across Karachi, Hyderabad, Lahore, Multan, and Rawalpindi. Participants Adolescents with a recent history of self-harm identified at participating health centres by treating physicians between 5 November 2019 and 31 August 2021. Intervention The YCMAP group received up to 10 treatment sessions over three months; the intervention was based on the principles of cognitive behaviour therapy. Main outcome measure The primary outcome was the repetition of self-harm at 12 months after randomisation. Secondary outcomes were distress, hopelessness, suicidal ideation, and health related quality of life at three, six, nine, and 12 months after randomisation. Participants’ satisfaction with the services was assessed at three and 12 months after randomisation. Results This trial was conducted between November 2019 and February 2023 and included 684 adolescents randomised to YCMAP (n=342) or enhanced treatment as usual (n=342). The YCMAP group had a significantly lower risk of self-harm repetition than the enhanced treatment as usual group at 12 months after randomisation (odds ratio 0.20, 95% confidence interval 0.06 to 0.70, P=0.006). YCMAP participants showed a statistically significant reduction in distress, hopelessness, and suicidal ideation at three months, but these differences were not statistically significant at 12 months. YCMAP participants also reported significantly better quality of life and satisfaction with services at three months, with these effects sustained at all follow-up points. Conclusion The YCMAP intervention was shown to be beneficial in self-harm prevention among adolescents. Further research and replication of findings in diverse settings are recommended to strengthen the evidence base for this public health intervention. Trial registration ClinicalTrials.gov NCT04131179 and ISRCTN registry ISRCTN57325925.


  • Open Access

    Equity and capacity to benefit from early access to medicines schemes

    by Sarah J. L. Edwards, Paul Aliu, Joe Brierley, Søren Holm, Peter J. Pitts

    Many diseases, especially rare ones, have not gained the attention or support needed to attract dedicated research interest to be able to develop successful medicines. There is, thus, a significant unmet clinical need, not all of which is (or indeed can be) addressed through the evaluation of investigational treatments introduced within the confines of clinical trials. People with severe life-threatening conditions who are not eligible to participate in any ongoing clinical trials may be able to try investigational medicines through schemes facilitating early use of or expanded access to innovative medicines. Here, we focus on the issue of equity in such programmes. Standard metrics of clinical need which inform operational decisions about equity in resource allocation primarily rely on social goods which have already been evaluated, providing evidence to support the standard assessment of patient ‘capacity to benefit’ from given medical interventions. Notions of equity have only relatively recently been discussed within research and innovation generally and within the ethics of clinical trials in particular. Considerations of equity, however, require an overview of all these different patient pathways. We suggest that a new formal method to assess eligibility for early use of or expanded access to innovative medicines be used to capture both the severity of the condition and capacity for scientific or social value alongside clinical trials.


  • Open Access

    Ethics to inform decision-making

    by Sarah J.L. Edwards, Caitlin Gordon, Blessing Silaigwana, Roli Mathur

    Ethical considerations are an important part of decision-making processes at each stage of an infectious disease emergency. This chapter introduces the notion that ethical thinking begins with a process of clarification of the values and moral principles at work in decision-making, and evolves a set of procedures to reason morally in each decision-making context. Certain moral concepts are necessary to highlight in the ethics of infectious disease emergencies, particularly ideas of autonomy, beneficence, and justice. The chapter then works through the different phases of emergency response, introducing the key ethical issues and questions at each phase. Ethical thinking does not provide single ideal answers, but enables decision-makers to identify and articulate the value components of decisions, so as to balance, for example, considerations of individual liberties with public health outcomes in an emergency. Elaborate processes of consideration and consultation are often in tension with the challenges of making critical decisions rapidly and under uncertainty. That is why trustworthy institutions and continued community engagement are crucial, particularly in culturally diverse settings. The chapter concludes by emphasising the need for ongoing ethical reflection and preparedness to better manage future outbreaks, advocating for a sustained social conversation on the balance between protecting public health and respecting individual rights.

  • Open Access

    Considerations for prioritising clinical research using bacteriophage

    by Sarah J.L. Edwards, Yiran Tao, Rodas Elias, Robert Schooley

    Antimicrobial resistance (AMR) poses a significant global health threat, as it contributes to prolonged illness, higher mortality rates and increased healthcare costs. As traditional antibiotics become less effective, treatments such as bacteriophage therapy offer potential solutions. The question remains, however, on how to set research priorities in the face of a growing number of antibiotic-resistant pathogens, some common and/or dangerous. One standard way of making decisions about which research to prioritise is by using the disability-adjusted life year metric to estimate the current global impact of a disease or condition, combined with considerations of social justice although decisions made at a national level by governments, especially in low income countries with forecasting potential over future needs may look very different. Another approach is based on the needs of researchers and regulators given what we know about the technology itself. The biological characteristics of bacteriophage therapies set challenges to a universal and standardised prioritisation method. A proof of principle is still arguably needed. With a preliminary discussion of the scope and complexity of AMR and AMR therapeutics, we propose some implications of regulatory frameworks aiming to integrate bacteriophage therapy into mainstream medical practice while gathering scientific data on safety and efficacy, enhancing the collective action needed to combat AMR.


  • Open Access

    Pandemic lockdowns: who feels coerced and why? - a study on perceived coercion, perceived pressures and procedural justice during the UK COVID-19 lockdowns

    by V. Ranieri, C. Gordon, S. K. Kamboj, S. J. Edwards

    Background: This study examined perceptions of coercion, pressures and procedural injustice and how such perceptions influenced psychological well-being in those who experienced a UK COVID-19 lockdown, with a view to preparing for the possibility of future lockdowns. Methods: 40 individuals categorised as perceiving the lockdown(s) as either highly or lowly coercive took part in one of six asynchronous virtual focus groups (AVFGs). Results: Using thematic analysis, the following key themes were identified in participants’ discussions: (1) Choice, control and freedom; (2) threats; (3) fairness; (4) circumstantial factors; and (5) psychological factors. Conclusions: As the first qualitative study to investigate the psychological construct of perceived coercion in relation to COVID-19 lockdowns, its findings suggest that the extent to which individuals perceived pandemic-related lockdowns as coercive may have been linked to their acceptance of restrictions. Preparing for future pandemics should include consideration of perceptions of coercion and efforts to combat this, particularly in relation to differences in equity, in addition to clarity of public health messaging and public engagement.


  • Open Access

    An ethics of anthropology‐informed community engagement with COVID‐19 clinical trials in Africa

    by Sarah J. L. Edwards, Blessing Silaigwana, Danny Asogun, Julius Mugwagwa, Francine Ntoumi, Rashid Ansumana, Kevin Bardosh, Jennyfer Ambe

    The COVID‐19 pandemic has reinforced the critical role of ethics and community engagement in designing and conducting clinical research during infectious disease outbreaks where no vaccine or treatment already exists. In reviewing current practices across Africa, we distinguish between three distinct roles for community engagement in clinical research that are often conflated: 1) the importance of community engagement for identifying and honouring cultural sensitivities; 2) the importance of recognising the socio‐political context in which the research is proposed; and 3) the importance of understanding what is in the interest of communities recruited to research according to their own views and values. By making these distinctions, we show that current practice of clinical research could draw on anthropology in ways which are sometimes unnecessary to solicit local cultural values, overlook the importance of socio‐political contexts and wider societal structures within which it works, potentially serving to reinforce unjust political or social regimes, and threaten to cast doubt on the trustworthiness of the research. We argue that more discerning anthropological engagement as well as wider collaboration with other social scientists and those working in the humanities is urgently needed to improve the ethics of current biomedical and pharmaceutical research practice in Africa.


  • Top Cited Papers
    Open Access

    Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts

    by Eskild Petersen, Francine Ntoumi, David S Hui, Aisha Abubakar, Laura D. Kramer, Christina Obiero, Paul Anantharajah Tambyah, Lucille Blumberg, Richard Yapi, Seif Al-Abri, et al.


  • Limitations to Contingency Measures: Reflections from COVID-19 Surges in the UK

    by Caitlin Gordon, Sarah Yardley, David A. Lomas, Sarah J. L. Edwards

    Alfandre et al. (2021) helpfully outlines the case for attending to contingency planning as well as to crisis measures during a pandemic. The authors provides a helpful framework for reflecting on ...


  • Open Access

    Anthroponotic risk of SARS-CoV-2, precautionary mitigation, and outbreak management

    by Sarah J L Edwards, Joanne M Santini